Journal
BIOANALYSIS
Volume 10, Issue 18, Pages 1525-1546Publisher
FUTURE SCI LTD
DOI: 10.4155/bio-2018-0135
Keywords
Alzheimer's disease; biomarker; dementia; lipidomics; mass spectrometry; metabolomics; mild cognitive impairment; untargeted metabolomics
Ask authors/readers for more resources
Alzheimer's disease (AD) is a complex disease driven mainly by neuronal loss due to accumulation of intracellular neurofibrillary tangles and amyloid aggregates in the brain. The diagnosis of AD currently relies on clinical symptoms while the disease can only be confirmed at autopsy. The few available biomarkers allowing for diagnosis are typically detected many years after the onset of the disease. New diagnostic approaches, particularly in easily-accessible biofluids, are essential. By providing an exhaustive information of the phenotype, metabolomics is an ideal approach for identification of new biomarkers. This review investigates the current position of metabolomics in the field of AD research, focusing on animal and human studies, and discusses the improvements carried out over the past decade.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available